BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Thomas M. Finnerty as its Chief Human Resources Officer. Mr. Finnerty brings a 25-year track record of building global human resources teams, and specializes in talent acquisition and development, executive coaching, and employee engagement. After spending the last three months in a strategic human capital consulting role with Anika, Mr. Finnerty will transition to this newly-created position on October 30, 2017. He will be responsible for spearheading strategic talent acquisitions at Anika’s U.S. and European headquarters, and overseeing professional development and employee relations initiatives.
“As we build out our commercial operations and expand our global footprint, talent acquisition and retention will be of critical importance,” said Charles H. Sherwood, Ph.D., Chief Executive Officer of Anika Therapeutics. “We are pleased to strengthen our executive leadership team with a seasoned human resources specialist like Mr. Finnerty. With more than two decades of expertise leading human resources operations for global medical device companies, Tom is well-positioned to support Anika’s next decade of growth.”
Most recently, Mr. Finnerty spent 17 years as Senior Vice President of Human Resources at Smith & Nephew, a global medical device leader with 14,000 employees worldwide. Prior to his time at Smith & Nephew, Mr. Finnerty served as Executive Director of Human Resources at Novartis/Chiron Diagnostics.
“Anika is on the cusp of a major transformation, and joining the executive team as the human resources lead presents an exciting opportunity to further expand and build out its human capital programs and initiatives,” said Thomas M. Finnerty, Chief Human Resources Officer of Anika Therapeutics.
Mr. Finnerty began his human resources career at The Foxboro Company, a global enterprise focused on designing and manufacturing innovative process control products and systems. He holds a Masters in Business Administration from Babson College, and Bachelor of Science in Business from the University of Massachusetts.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171023006268/en/
For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
For Media Inquiries:
Sonal Vasudev, 917-523-1418
Source: Anika Therapeutics, Inc.